N-[2-(4-chloro-2-trifluoromethyl-phenyl)-1,1-dimethyl-ethyl]-formamide | 1218792-54-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-[2-(4-chloro-2-trifluoromethyl-phenyl)-1,1-dimethyl-ethyl]-formamide
• 英文别名: N-[1-[4-chloro-2-(trifluoromethyl)phenyl]-2-methylpropan-2-yl]formamide
• CAS: 1218792-54-1
• 化学式: C₁₂H₁₃ClF₃NO
• 分子量: 279.69
• InChiKey: STTZKXJQYNDSCH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-[2-(4-chloro-2-trifluoromethyl-phenyl)-1,1-dimethyl-ethyl]-formamide 在 盐酸 作用下， 以 乙醚 为溶剂， 生成 C₁₁H₁₃ClF₃N
  参考文献：
  名称：

  Discovery of olodaterol, a novel inhaled β2-adrenoceptor agonist with a 24h bronchodilatory efficacy

  摘要：

  Compound 4p was identified from a series of 6-hydroxy-4H-benzo[1,4]oxazin-3-ones as potent agonist of the human beta(2)-adrenoceptor with a high beta(1)/beta(2)-selectivity. A complete reversal of acetylcholine-induced bronchoconstriction which lasted over the whole study period of 5 h was demonstrated for 4p in a guinea pig in vivo model without any signs of cardiovascular effects up to 10-fold above the first dose reaching 100% bronchoprotection. The enantiomerically pure (R)-form of 4p exerted a bronchodilatory efficacy over 24 h in dogs and guinea pigs in the absence of systemic pharmacodynamic effects. Formoterol which was tested as comparator in the same in vivo models of acetylcholine-induced bronchoconstriction did not retain efficacy after 24 h. In summary, the preclinical pro. le of compound (R)-4p (olodaterol, also known as BI 1744 CL) suggests a potential for once-daily dosing in man accompanied with an improved safety pro. le. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.12.087
• 作为产物：
  描述：

  sodium cyanide 、 4-Chloro-1-(2-methyl-propenyl)-2-trifluoromethyl-benzene 在 硫酸 、 溶剂黄146 作用下， 生成 N-[2-(4-chloro-2-trifluoromethyl-phenyl)-1,1-dimethyl-ethyl]-formamide
  参考文献：
  名称：

  Discovery of olodaterol, a novel inhaled β2-adrenoceptor agonist with a 24h bronchodilatory efficacy

  摘要：

  Compound 4p was identified from a series of 6-hydroxy-4H-benzo[1,4]oxazin-3-ones as potent agonist of the human beta(2)-adrenoceptor with a high beta(1)/beta(2)-selectivity. A complete reversal of acetylcholine-induced bronchoconstriction which lasted over the whole study period of 5 h was demonstrated for 4p in a guinea pig in vivo model without any signs of cardiovascular effects up to 10-fold above the first dose reaching 100% bronchoprotection. The enantiomerically pure (R)-form of 4p exerted a bronchodilatory efficacy over 24 h in dogs and guinea pigs in the absence of systemic pharmacodynamic effects. Formoterol which was tested as comparator in the same in vivo models of acetylcholine-induced bronchoconstriction did not retain efficacy after 24 h. In summary, the preclinical pro. le of compound (R)-4p (olodaterol, also known as BI 1744 CL) suggests a potential for once-daily dosing in man accompanied with an improved safety pro. le. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.12.087

文献信息

• Novel long acting betamimetics for the treatment of respiratory diseases
  申请人：Bouyssou Thierry

  公开号：US20050209227A1

  公开（公告）日：2005-09-22

  The present invention relates to the compounds of general formula 1 wherein the groups R, R 1 , R 2 , R 3 and A may have the meanings given in the claims and specification, processes for preparing them and their use as medicaments, particularly for the treatment of inflammatory and obstructive respiratory complaints.

  本发明涉及一般式1的化合物，其中基团R、R1、R2、R3和A可能具有在权利要求书和说明书中给出的含义，以及制备它们的过程和它们作为药物的用途，特别是用于治疗炎症和阻塞性呼吸疾病。
• Long acting betamimetics for the treatment of respiratory diseases
  申请人：Boehringer Ingelheim International GmbH

  公开号：US07244728B2

  公开（公告）日：2007-07-17

  The present invention relates to the compounds of general formula 1 wherein the groups R, R1, R2, R3 and A may have the meanings given in the claims and specification, processes for preparing them and their use as medicaments, particularly for the treatment of inflammatory and obstructive respiratory complaints.

  本发明涉及通式1的化合物，其中基团R、R1、R2、R3和A可能具有在权利要求和说明书中给出的含义，制备它们的过程以及它们作为药物的用途，特别是用于治疗炎症和阻塞性呼吸疾病。
• NEUE BENZOXAZINONDERIVATE ALS LANGWIRKSAME BETAMIMETIKA ZUR BEHANDLUNG VON ATEMWEGSERKRANKUNGEN
  申请人：BOEHRINGER INGELHEIM INTERNATIONAL GMBH

  公开号：EP1730126A1

  公开（公告）日：2006-12-13
• US7244728B2
  申请人：——

  公开号：US7244728B2

  公开（公告）日：2007-07-17
• [DE] NEUE BENZOXAZINONDERIVATE ALS LANGWIRKSAME BETAMIMETIKA ZUR BEHANDLUNG VON ATEMWEGSERKRANKUNGEN<br/>[EN] NOVEL BENZOXAZINONE DERIVATIVES USED AS LONG-ACTING BETAMIMETICS FOR TREATING RESPIRATORY ILLNESSES<br/>[FR] NOUVEAUX DERIVES DE BENZOXAZINONE UTILISES COMME BETA-MIMETIQUES DANS LE TRAITEMENT DES AFFECTIONS DES VOIES RESPIRATOIRES
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2005092870A1

  公开（公告）日：2005-10-06

  Die vorliegende Erfindung betrifft die Verbindungen der allgemeinen Formel (I), worin die Reste R, R1, R2, R3 und A die in den Ansprüchen und in der Beschreibung genannten Bedeutungen haben können, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel, insbesondere zur Behandlung von entzündlichen und obstruktiven Atemwegserkrankungen.